Literature DB >> 12527204

Genomic structure of the human BCCIP gene and its expression in cancer.

Xiangbing Meng1, Jingmei Liu, Zhiyuan Shen.   

Abstract

Human BCCIPalpha (Tok-1alpha) is a BRCA2 and CDKN1A (Cip1, p21) interacting protein. Our previous studies have showed that overexpression of BCCIPalpha inhibits the growth of certain tumor cells [Oncogene 20 (2001) 336]. In this study, we report the genomic structure of the human BCCIP gene, which contains nine exons. Alternative splicing of the 3'-terminal exons produces two isoforms of BCCIP transcripts, BCCIPalpha and BCCIPbeta. The BCCIP gene is flanked by two genes that are transcribed in the opposite orientation of the BCCIP gene. It lies head-to-head and shares a bi-directional promoter with the uroporphyrinogen III synthase (UROS) gene. The last three exons of BCCIP gene overlap the 3'-terminal seven exons of a DEAD/H helicase-like gene (DDX32). Using a matched normal/tumor cDNA array, we identified a reduced expression of BCCIP in kidney tumor, suggesting a role of BCCIP in cancer etiology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527204     DOI: 10.1016/s0378-1119(02)01098-3

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  30 in total

1.  The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair.

Authors:  Huimei Lu; Xu Guo; Xiangbing Meng; Jingmei Liu; Chris Allen; Justin Wray; Jac A Nickoloff; Zhiyuan Shen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

2.  Expression pattern of BCCIP in hepatocellular carcinoma is correlated with poor prognosis and enhanced cell proliferation.

Authors:  Zhipeng Lin; Baoying Hu; Wenkai Ni; Xiaofei Mao; Huiling Zhou; Jiale Lv; Bihui Yin; Zhongyi Shen; Miaomiao Wu; Wensen Ding; Mingbing Xiao; Runzhou Ni
Journal:  Tumour Biol       Date:  2016-11-10

3.  High Expression of BCCIP β Can Promote Proliferation of Esophageal Squamous Cell Carcinoma.

Authors:  Lingling Chen; Sujie Ni; Mei Li; Chaoyan Shen; Zhipeng Lin; Yu Ouyang; Fei Xia; Li Liang; Wenyan Jiang; Runzhou Ni; Jianguo Zhang
Journal:  Dig Dis Sci       Date:  2016-12-19       Impact factor: 3.199

4.  DHX32 expression is an indicator of poor breast cancer prognosis.

Authors:  Meng Wang; Guojun Zhang; Yajie Wang; Ruimin Ma; Limin Zhang; Hong Lv; Fang Fang; Xixiong Kang
Journal:  Oncol Lett       Date:  2016-12-14       Impact factor: 2.967

5.  Abrogation of the transactivation activity of p53 by BCCIP down-regulation.

Authors:  Xiangbing Meng; Jingyin Yue; Zhihe Liu; Zhiyuan Shen
Journal:  J Biol Chem       Date:  2006-11-29       Impact factor: 5.157

6.  Regulation of PI4,5P2 synthesis by nuclear-cytoplasmic shuttling of the Mss4 lipid kinase.

Authors:  Anjon Audhya; Scott D Emr
Journal:  EMBO J       Date:  2003-08-15       Impact factor: 11.598

7.  BCCIP is required for the nuclear localization of the p21 protein.

Authors:  Jinjiang Fan; Justin Wray; Xiangbing Meng; Zhiyuan Shen
Journal:  Cell Cycle       Date:  2009-09-25       Impact factor: 4.534

8.  Roles of BCCIP in chromosome stability and cytokinesis.

Authors:  X Meng; J Fan; Z Shen
Journal:  Oncogene       Date:  2007-04-23       Impact factor: 9.867

9.  Distinct RAD51 associations with RAD52 and BCCIP in response to DNA damage and replication stress.

Authors:  Justin Wray; Jingmei Liu; Jac A Nickoloff; Zhiyuan Shen
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

10.  BCCIP suppresses tumor initiation but is required for tumor progression.

Authors:  Yi-Yuan Huang; Li Dai; Dakim Gaines; Roberto Droz-Rosario; Huimei Lu; Jingmei Liu; Zhiyuan Shen
Journal:  Cancer Res       Date:  2013-10-21       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.